Consensus Q32 Bio Inc.

Equities

QTTB

US7469641051

Delayed Nasdaq Other stock markets 10:11:27 2024-04-24 am EDT			5-day change	1st Jan Change
26.22 ^USD	+2.80%		+8.69%	+133.00%

Apr. 11	Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target	MT
Apr. 03	Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer	CI

Evolution of the average Target Price on Q32 Bio Inc.

Price target over the last 5 years

History of analyst recommendation changes

83b1968d.R64HBdctTBAcXtsvAhiuyTTaymQZlY-QNntjcqsKE5E.FttAb-Z4eEh1Nu5BZTWclnqFqAh-x-DRRD8JB4ZhJMAMl3ZfgR08XCQvjg~f2f8924ceafcf1314ae74983bb20a31e

Analyst Recommendations on Q32 Bio Inc.

Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target	Apr. 11	MT
Piper Sandler Initiates Q32 Bio With Overweight Rating, $45 Price Target	Apr. 02	MT
Baird Downgrades Homology Medicines to Neutral From Outperform, Adjusts Price Target to $1.50 From $9	23-07-28	MT
Chardan Cuts Price Target on Homology Medicines to $7 From $8, Maintains Buy Rating	23-05-12	MT
Chardan Lowers Price Target on Homology Medicines to $8 From $10, Keeps Buy Rating	22-11-17	MT
RBC Cuts Price Target on Homology Medicines to $3 From $4, Maintains Sector Perform, Speculative Risk	22-11-11	MT
Baird Adjusts Price Target on Homology Medicines to $9 From $10, Keeps Outperform Rating	22-08-31	MT
Chardan Lowers Homology Medicines' Price Target to $10 From $14, Maintains Buy Rating	22-08-16	MT
BTIG Adjusts Price Target on Homology Medicines to $12 From $29, Reiterates Buy Rating	22-08-16	MT
Chardan Trims Homology Medicines' Price Target to $14 From $15, Reiterates Buy Rating	22-05-17	MT
Credit Suisse Initiates Homology Medicines at Neutral, $2.70 Price Target	22-04-28	MT
Canaccord Genuity Adjusts Homology Medicines' Price Target to $7 From $19, Maintains Buy Rating	22-04-06	MT
HC Wainwright Adjusts Homology Medicines' Price Target to $20 from $30, Keeps Buy Rating	22-02-28	MT
BofA Securities Adjusts Homology Medicines' Price Target to $9 from $25, Keeps Buy Rating	22-02-22	MT
Homology Medicines Shares Dive 30% to 52-Week Low After Trial Hold, Analysts Cuts	22-02-22	DJ
Chardan Lowers Homology Medicines PT to $15 From $25 After FDA's Clinical Hold on PheNIX Based on Clinical Observations, Maintains Buy Rating	22-02-22	MT
Oppenheimer Downgrades Homology Medicines to Perform From Outperform, Removes $22 Price Target	22-02-22	MT
Homology Medicines Shares Drop 27% After Gene Therapy Trial Halted By FDA	22-02-22	DJ
RBC Downgrades Homology Medicines to Sector Perform From Outperform, Price Target Slashed to $4 From $30, Shares Fall 25%	22-02-22	MT
Baird Adjusts Homology Medicines' Price Target to $10 From $16, Maintains Outperform Rating	22-02-22	MT
BTIG Adjusts Homology Medicines' Price Target to $29 From $35, Reiterates Buy Rating	22-02-22	MT
Chardan Adjusts Homology Medicines' Price Target to $25 From $30; Buy Rating Kept	21-11-16	MT
HOMOLOGY MEDICINES : Oppenheimer Adjusts Homology Medicines PT to $22 From $24, Maintains Outperform Rating	21-10-13	MT
HOMOLOGY MEDICINES : Canaccord Genuity Adjusts Homology Medicines' Price Target to $19 From $37, Maintains Buy Rating	21-05-18	MT
HOMOLOGY MEDICINES : Chardan Adjusts Price Target on Homology Medicines to $30 From $32, Maintains Buy Rating	21-05-10	MT